The MISSION® siRNA Transfection Reagent is for the transfection of siRNA to achieve ≥90% silencing efficiency for transient knockdown of eukaryotic gene expression. Effective gene silencing and reduced off target effects are achieved using a low siRNA concentration (1nM). The siRNA Transfection Reagent is provided as a sterile solution, and is compatible with serum and antibiotics.
Other Notes
Gene silencing assay: An A549 cell line stably expressing firefly luciferase was transfected in 24-well plates with 8.4 ng of 21-mer Luciferase siRNA using 2 μL of the MISSION® siRNA Transfection Reagent. Experiments were performed in triplicate in presence of serum. Cell lysates were assessed for luciferase expression 48 hours post-transfection.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
It was recently shown that the 5' to 3' exoribonuclease XRN2 is involved in the DNA damage response. Importantly, loss of XRN2 abrogates DNA double stranded break repair via the non-homologous end-joining pathway. However, the mechanistic details of how XRN2
International journal of molecular sciences, 21(12) (2020-06-19)
Cellular survival is dependent on the efficient replication and transmission of genomic information. DNA damage can be introduced into the genome by several different methods, one being the act of DNA replication. Replication is a potent source of DNA damage
Hyperactivation of the PI3K/AKT pathway is observed in most human cancer including lung carcinomas. Here we have investigated the role of miRNAs as downstream targets of activated PI3K/AKT signaling in Non Small Cell Lung Cancer (NSCLC). To this aim, miRNA
Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are
Journal of the American Society of Nephrology : JASN, 30(12), 2370-2383 (2019-11-05)
Sustained activation of EGF receptor (EGFR) in proximal tubule cells is a hallmark of progressive kidney fibrosis after AKI and in CKD. However, the molecular mechanisms and particular EGFR ligands involved are unknown. We studied EGFR activation in proximal tubule
Sigma-Aldrich® Advanced Genomics is the leading provider of gene editing and silencing technologies including CRISPR, Cas9, synthetic guide RNA (sgRNA), and Zinc Finger Nuclease (ZFN).
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
